Cell No. : Cell Name
RCB5451 : PrimPol-TK6
update : 2024/03/27
|
| Comment | |
| Comment from the depositor | TK6 cells are one of the most commonly used human B lymphocyte-derived cell for cancer research. PrimPol- disrupted TK6 cells. |
| Terms and conditions | The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit organization for a not-for profit research. |
| Remarks | CRISPR/Cas9 genome edited bioresources Announcement of bioresources developed by the CRISPR/Cas9 technology. |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0065.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
TAKEDA, Shunichi & SASANUMA, Hiroyuki
|
| Originator |
TAKEDA, Shunichi & SASANUMA, Hiroyuki
|
| Year of deposit |
2021
|
| Another name |
PrimPol-/--
|
| Original cell |
TK6
|
| Cloning (depositor) |
Yes
|
| _Date (depositor) |
2019
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
5 years
|
| Tissue |
spleen
|
| Disease name |
Hereditary spherocytosis
|
| Classification |
transformed
|
| Recombinant |
recombinant
|
|
2000
base
|
| Vector |
DT-ApA/MARKERR-
|
| Recombinant virus |
No
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Contact inhibition |
No
|
| Tumorigenesis |
No
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Suspension cells
|
Suspension cells
|
| Culture medium |
RPMI1640, Horse serum 10%, Sodium pyruvate 0.2mg/ml
|
RPMI1640 + 10% HS + 0.2mg/ml Sodium pyruvate
|
| Culture method |
|
|
| Antibiotics |
Penicillin / Streptomycin
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage cell No |
> 0.1x10 6 cells/ml
|
1x10 5/mL
|
| Passage ratio |
|
1 : 10-20 split
|
| SC frequency |
|
3 times/week
|
| Temperature |
37
℃
|
37
℃
|
| CO2 concentration |
5
%
|
5
%
|
| Freeze medium |
Cell Freezing Reagents
|
CELLBANKER 1
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
(-)
|
(-)
|
| Animal PCR |
|
OK
|
| Virus (HIV) |
|
Undetected
|
| Virus (HTLV-1) |
|
(-)
|
| Virus (EBV) |
|
(+)
|
| Chromosome mode |
Trisomy 13
|
|
| Saturation density |
1x10 6 cells/ml
|
|
| Doubling time |
13
hr
|
|
| Plating efficiency |
70
%
|
|
| STR(human) |
|
OK
|
| Reference information |
Reference |
4
|
| User's Publication |
0
|
| Reference |
|
17840
Tsuda M, Ogawa S, Ooka M, Kobayashi K, Hirota K, Wakasugi M, Matsunaga T, Sakuma T, Yamamoto T, Chikuma S, Sasanuma H, Debatisse M, Doherty AJ, Fuchs RP, Takeda S.
PDIP38/PolDIP2 controls the DNA damage tolerance pathways by increasing the relative usage of translesion DNA synthesis over template switching
PLoS One
2019
14(3):e0213383
PubMed ID: 30840704
DOI: 10.1371/journal.pone.0213383
|
|
279
Skopek TR, Liber HL, Penman BW, Thilly WG.
Isolation of a human lymphoblastoid line heterozygous at the thymidine kinase locus: possibility for a rapid human cell mutation assay
Biochem Biophys Res Commun
1978
84(2):411-6
PubMed ID: 214074
DOI: 10.1016/0006-291x(78)90185-7
|
|
281
Levy JA, Buell DN, Creech C, Hirshaut Y, Silverberg H.
Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines
J Natl Cancer Inst
1971
46(3):647-54
PubMed ID: 4323138
|
|
280
Levy JA, Virolainen M, Defendi V.
Human lymphoblastoid lines from lymph node and spleen
Cancer
1968
22(3):517-24
PubMed ID: 5673231
DOI: 10.1002/1097-0142(196809)22:3<517::aid-cncr2820220305>3.0.co;2-a
|
Back
Top
CELL BANK Website